|

Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes

RECRUITINGPhase 2Sponsored by Tan Tock Seng Hospital
Actively Recruiting
PhasePhase 2
SponsorTan Tock Seng Hospital
Started2025-07-24
Est. completion2027-07-31
Eligibility
Age21 Years – 80 Years
Healthy vol.Accepted

Summary

This study will test whether a low-cost anti-inflammatory medicine called colchicine can help protect the blood vessels of people with type 2 diabetes. Diabetes speeds up hardening of the arteries (atherosclerosis), partly because of ongoing low-grade inflammation. Colchicine has already been shown to help prevent heart attacks and strokes in people who already have heart disease; this study looks at whether it can also help prevent early blood vessel damage before heart disease develops. Around 300 adults with type 2 diabetes will be randomly assigned to take colchicine or a placebo (dummy pill) once daily for 24 weeks, in addition to their usual diabetes and heart-risk medications. Neither participants nor the study team will know who is taking colchicine or placebo. The main measurement will be the change in the thickness of the wall of the neck (carotid) artery, measured by ultrasound, which is an early sign of blood vessel disease. The study will also look at markers of inflammation in the blood, blood vessel stiffness and function, and changes in the gut bacteria.

Eligibility

Age: 21 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* T2DM on stable diabetes medications (no change in last 3 months)
* At least one other comorbidity of hypertension, dyslipidaemia and/or obesity (BMI ≥27), with no previous history of ASCVD
* Able to provide informed consent

Exclusion Criteria:

1. Recent hospitalization or acute infections within last 2 weeks.
2. Current Treatment with corticosteroids or immunosuppressive agents
3. Pre-existing malignancies or other terminal conditions with limited prognosis
4. Pregnancy
5. Breastfeeding
6. Inability to provide written consent
7. Renal impairment (eGFR\< 60ml/min)
8. Liver cirrhosis or ALT/AST \>3x ULN
9. Pharmacogenomics indicative of adverse effects
10. Hypersensitivity to the active substance or to the following excipients: Lactose, Maize starch, Sodium laurilsulfate, Magnesium stearate
11. Known blood dyscrasia
12. Women of childbearing age who are keen to conceive in the next 1 year
13. Taking a strong P-glycoprotein inhibitor (e.g. cyclosporine, ranolazine) or a strong CYP3A4 inhibitor
14. Known myositis with raised creatine kinase with statins (statin myopathy).
15. Gout attack within the last 1 year
16. Currently taking Aspirin
17. Taking any oral contraceptives

Conditions4

AtherosclerosisCardiovascular DiseasesDiabetesType 2 Diabetes Mellitus (T2DM)

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.